Search
LX-7101
go.drugbank.com/drugs/DB16009InvestigationalLX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).
Aganepag isopropyl
go.drugbank.com/drugs/DB16085InvestigationalAganepag isopropyl is under investigation in clinical trial NCT01110499 (Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or
D3S-001
go.drugbank.com/drugs/DB19008InvestigationalD3S-001 is under investigation in clinical trial NCT05410145 (A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.g12c Mutation).
Fursultiamine
go.drugbank.com/drugs/DB08966ApprovedCompound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
LX1031
go.drugbank.com/drugs/DB05199InvestigationalLX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. … LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system
NV-52
go.drugbank.com/drugs/DB05673ExperimentalNV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.
Denibulin
go.drugbank.com/drugs/DB05932ExperimentalDenibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Navocaftor
go.drugbank.com/drugs/DB19039InvestigationalNavocaftor is under investigation in clinical trial NCT04853368 (Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/navocaftor/abbv-119 or Galicaftor/navocaftor
XL820
go.drugbank.com/drugs/DB05146InvestigationalXL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia. … PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of
Bleomycin A6
go.drugbank.com/drugs/DB12992InvestigationalThe development of this drug, apparently, was discontinued. … This drug participated in clinical trials for the treatment of Squamous Cell Lung Cancer.